Consensus Statements on Precision Oncology in the China Greater Bay Area

Tai-Chung Lam, William Chi-Shing Cho, Joseph Siu-Kie Au, Edmond Shiu-Kwan Ma, Stephen Tak-Sum Lam, Herbert Ho-Fung Loong, Jason Wing Hon Wong, S.N. Michael Wong, Victor Ho-Fun Lee, Roland Ching-Yu Leung, Johnny Kin-Sang Lau, Michael Tsz-Yeung Kam, Florence Siu-Ting Mok, Fiona Mei-Ying Lim, Jonathan Shi-Feng Nyaw, Winnie Wing-Yan Tin, Ka-Man Cheung, Oscar Siu-Hong Chan, Philip Wai-Kay Kwong, Foon-Yiu CheungDarren M.C. Poon, Jeannie Yin-Kwan Chik, Martin Ho-Ching Lam, Lawrence Wing-Chi Chan, Sze-Chuen Cesar Wong, Ya-Bing Cao, Cheng-Vai Hui, Jack Zhi-Jian Chen, Jian-Hua Chang, Spring Feng-Ming Kong, Aya El Helali

Research output: Journal article publicationJournal articleAcademic researchpeer-review

1 Citation (Scopus)

Abstract

BACKGROUNDNext-generation sequencing comprehensive genomic panels (NGS CGPs) have enabled the delivery of tailor-made therapeutic approaches to improve survival outcomes in patients with cancer. Within the China Greater Bay Area (GBA), territorial differences in clinical practices and health care systems and strengthening collaboration warrant a regional consensus to consolidate the development and integration of precision oncology (PO). Therefore, the Precision Oncology Working Group (POWG) formulated standardized principles for the clinical application of molecular profiling, interpretation of genomic alterations, and alignment of actionable mutations with sequence-directed therapy to deliver clinical services of excellence and evidence-based care to patients with cancer in the China GBA.METHODSThirty experts used a modified Delphi method. The evidence extracted to support the statements was graded according to the GRADE system and reported according to the Revised Standards for Quality Improvement Reporting Excellence guidelines, version 2.0.RESULTSThe POWG reached consensus in six key statements: harmonization of reporting and quality assurance of NGS; molecular tumor board and clinical decision support systems for PO; education and training; research and real-world data collection, patient engagement, regulations, and financial reimbursement of PO treatment strategies; and clinical recommendations and implementation of PO in clinical practice.CONCLUSIONPOWG consensus statements standardize the clinical application of NGS CGPs, streamline the interpretation of clinically significant genomic alterations, and align actionable mutations with sequence-directed therapies. The POWG consensus statements may harmonize the utility and delivery of PO in China's GBA.
Original languageEnglish
Pages (from-to)e2200649
JournalJCO Precision Oncology
Issue number7
DOIs
Publication statusPublished - Jun 2023

Fingerprint

Dive into the research topics of 'Consensus Statements on Precision Oncology in the China Greater Bay Area'. Together they form a unique fingerprint.

Cite this